Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

1190 - Investigating the combination of bevacizumab and the EGF receptor inhibitor erlotinib for the treatment of metastatic renal cell carcinoma


10 Oct 2016


Poster display


Renaud Grepin


Annals of Oncology (2016) 27 (6): 526-544. 10.1093/annonc/mdw392


R. Grepin1, M. Guyot2, J. Durivault1, B. Front1, D. Ambrosetti3, G. Pagès2

Author affiliations

  • 1 Medical Biology, Centre Scientifique de Monaco, 98000 - Monaco/MC
  • 2 Cnrs Umr 7284/inserm U 1081, University Nice Sophia Antipolis, Institute for Research on Cancer and Aging, Nice/FR
  • 3 Laboratoire Central D’anatomopathologie, Hôpital Pasteur, Nice/FR


Abstract 1190


One of the major characteristics of metastatic clear cell renal cell carcinomas (RCC) is the over-expression of the Vascular Endothelial Growth Factor (VEGF). Several treatments against this pro-angiogenic factor are usually used such as sunitinib or the anti-VEGF bevacizumab (BVZ). In a mouse experimental model of RCC we have described that BVZ accelerated tumor growth. A down-regulation of phospho tyrosine phosphatase receptor kappa (PTPRk) by tumor cells under the selection pressure exerted during BVZ treatment is a potential explanation for this accelerated growth. The main target of PTPRk is the Epidermal Growth Factor Receptor (EGFR). Thus, down-regulation of PTPRk leads to a constitutive activation of the EGFR. According to the literature BVZ combined with ERLO does not benefit patients. However, the EGFR mutations were not checked in this clinical study. Considering these data, a combination of an inhibitor of EGFR (erlotinib/Tarceva) with the BVZ/interferon alpha (INF) treatment could be more efficient against RCC growth.


Tumor cells were injected subcutaneously, bioluminescence was quantified by using an in vivo Imaging System.


The BVZ/INF/ERLO treatment strongly reduced tumor volume and no tumor relapse has been observed compared to the reference treatment sunitinib. The triple combination reduces the production of redundant pro-angiogenic/pro-inflammatory cytokines of the ELR + CXCL family and induces a polarization of macrophages towards the M1 phenotype. The number of lymphatic vessels is inferior in tumors receiving this combination compared to the tumors of BVZ/INF or ERLO treated mice. Although no study has shown that BVZ combined with ERLO does not benefit patients, the EGFR mutations were not checked in this clinical study. Based on cells isolated from human RCC tumors we have identified a new mutation of the EGFR in human RCC, which could discriminate sensitive and insensitive patients to ERLO.


Together, our results indicate that BVZ/INF treatment could be more efficient in RCC if it is coupled to ERLO when a specific mutation of the EGFR is present. In conclusion BVZ/INF/ERLO is a relevant combination that deserves to be tested for the treatment of RCC.

Clinical trial identification

Legal entity responsible for the study

Centre Scientifique Monaco


Centre Scientifique Monaco


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings